Digest Network Come funziona
Network
/
Società
Es
Non verificato

Estrella Immunopharma, Inc.

Di cosa scriviamo

BiotecnologiaFarmaceuticaMedicina - VarieOncologiaSalute

20 comunicati stampa

Guarda tutti i comunicati
11/08/2026
Industria
Università
Biologia
Biotecnologia
Scuola/Istruzione
Salute
Sanità
Farmaceutica
Oncologia
HIV, AIDS e malattie autoimmuni
Medicina - Varie
Estrella Immunopharma Activates University Hospitals Cleveland Medical Center as Fourth Clinical Site for Phase I/II STARLIGHT-1 Trial in B-cell Non-Hodgkin’s Lymphoma
Fonte
Estrella Immunopharma, Inc.
Emittente
Business Wire
1.00
0
03/08/2026
Mercato del lavoro
Scienza
Biotecnologia
Medicina - Varie
Università
Farmaceutica
Salute
Scuola/Istruzione
Oncologia
Estrella Immunopharma Activates Oregon Health & Science University as Third Clinical Site for Phase I/II STARLIGHT-1 Trial in B-cell Non-Hodgkin’s Lymphoma
Fonte
Estrella Immunopharma, Inc.
Emittente
Business Wire
1.00
0
29/07/2026
Mercato del lavoro
Industria
Oncologia
Salute
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
Estrella Immunopharma Activates Baylor Scott & White Research Institute as Second Clinical Site for Phase I/II STARLIGHT-1 Trial in B-cell Non-Hodgkin’s Lymphoma
Fonte
Estrella Immunopharma, Inc.
Emittente
Business Wire
1.00
0
24/07/2026
Industria
Oncologia
Salute
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
Estrella Immunopharma Announces First Patient Dosed in Dose-Expansion Phase of STARLIGHT-1 Trial and Reports Durable Response Rate in Advanced B-Cell Non-Hodgkin’s Lymphoma
Fonte
Estrella Immunopharma, Inc.
Emittente
Business Wire
1.00
0
05/05/2026
Eventi
Biotecnologia
Farmaceutica
Salute
Oncologia
Estrella Immunopharma to Participate in the D. Boral Capital Global Conference
Fonte
Estrella Immunopharma, Inc.
Emittente
Business Wire
1.00
0
23/03/2026
Industria
Oncologia
Salute
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
Estrella Immunopharma, Inc. (NASDAQ: ESLA) Receives Initiating Coverage with a Valuation of $12.00/Share from Zacks Small-Cap Research
Fonte
Estrella Immunopharma, Inc.
Emittente
Business Wire
1.00
0
09/02/2026
Eventi
Industria
Oncologia
Salute
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
Estrella Immunopharma Presents Promising Updated Data on EB103 in Oral Presentation at the 2026 Tandem Meetings of ASTCT® & CIBMTR®
Fonte
Estrella Immunopharma, Inc.
Emittente
Business Wire
1.00
0
03/02/2026
Scienza
Biotecnologia
Farmaceutica
Oncologia
Sanità
Salute
Medicina - Varie
Eventi
Industria
Estrella Immunopharma Announces Late-Breaking Oral Presentation of Phase 1 STARLIGHT-1 Data for EB103 at the 2026 Tandem Meetings of ASTCT® & CIBMTR®
Fonte
Estrella Immunopharma, Inc.
Emittente
Business Wire
1.00
0
06/01/2026
Finanza
Oncologia
Salute
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
Estrella Immunopharma Announces Closing of $8.0 Million Registered Direct Offering and Concurrent Private Placement
Fonte
Estrella Immunopharma, Inc.
Emittente
Business Wire
1.00
0
05/01/2026
Finanza
Biotecnologia
Salute
Farmaceutica
Medicina - Varie
Oncologia
Estrella Immunopharma, Inc. Announces $8.0 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules
Fonte
Estrella Immunopharma, Inc.
Emittente
Business Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0